From Stockwatch today:
JAMIE MACKAY INCREASES POSITION IN REPLICEL LIFE SCIENCES INC.
"Jamie Mackay is issuing this press release pursuant to Part 3.1 of National Instrument 62-103 -- The Early Warning System and Related Take-Over Bid and Insider Reporting Issues, with respect to RepliCel Life Sciences Inc. Mr. Mackay is a 10-per-cent shareholder of the company.
On May 4, 2022, Mr. Mackay acquired 2,116,157 units from the company on a private placement basis at a price of 18 cents per unit for proceeds of $380,910, pursuant to a private placement subscription agreement. Each unit consists of one common share and one-half of one share purchase warrant. One warrant entitles the holder thereof to purchase one additional share of the company at a price of 40 cents per share.
Prior to the transaction, Mr. Mackay owned the following securities: (i) 2,546,870 shares held directly; and (ii) 1,117,917 warrants held directly to purchase an additional 1,117,917 shares. Prior to the transaction, Mr. Mackay directly owned 3,664,787 shares, on a partially diluted basis (assuming exercise of all warrants), which represented 9.24 per cent of the issued and outstanding shares as of May 3, 2022, based on 38,531,095 shares issued and outstanding as of such date.
Following the transaction, Mr. Mackay owned the following securities: (i) 4,663,037 shares held directly; and (ii) 2,176,000 warrants held directly to purchase an additional 2,176,000 shares. After the issuance of the units pursuant to the transaction, Mr. Mackay directly and indirectly owned and controlled 6,839,037 shares, on a partially diluted basis (assuming exercise of all warrants), which represents 15.22 per cent of the issued and outstanding shares as of May 4, 2022, based on 42,749,565 shares issued and outstanding as of such date.
Mr. Mackay acquired the securities of the company for investment purposes. Depending on economic or market conditions or matters relating to the company, Mr. Mackay may choose to either acquire additional securities or dispose of securities of the company. A copy of Mr. Mackay's early warning report will appear on the company's profile on SEDAR and may also be obtained by contacting Mr. Mackay."
Between Andrew Schutte and Jamie Mackay they currently own 30+% of the company. They must be seeing something us peasants are not privy to.
JAMIE MACKAY INCREASES POSITION IN REPLICEL LIFE SCIENCES INC.
Jamie Mackay is issuing this press release pursuant to Part 3.1 of National Instrument 62-103 -- The Early Warning System and Related Take-Over Bid and Insider Reporting Issues, with respect to RepliCel Life Sciences Inc. Mr. Mackay is a 10-per-cent shareholder of the company.
On May 4, 2022, Mr. Mackay acquired 2,116,157 units from the company on a private placement basis at a price of 18 cents per unit for proceeds of $380,910, pursuant to a private placement subscription agreement. Each unit consists of one common share and one-half of one share purchase warrant. One warrant entitles the holder thereof to purchase one additional share of the company at a price of 40 cents per share.
Prior to the transaction, Mr. Mackay owned the following securities: (i) 2,546,870 shares held directly; and (ii) 1,117,917 warrants held directly to purchase an additional 1,117,917 shares. Prior to the transaction, Mr. Mackay directly owned 3,664,787 shares, on a partially diluted basis (assuming exercise of all warrants), which represented 9.24 per cent of the issued and outstanding shares as of May 3, 2022, based on 38,531,095 shares issued and outstanding as of such date.
Following the transaction, Mr. Mackay owned the following securities: (i) 4,663,037 shares held directly; and (ii) 2,176,000 warrants held directly to purchase an additional 2,176,000 shares. After the issuance of the units pursuant to the transaction, Mr. Mackay directly and indirectly owned and controlled 6,839,037 shares, on a partially diluted basis (assuming exercise of all warrants), which represents 15.22 per cent of the issued and outstanding shares as of May 4, 2022, based on 42,749,565 shares issued and outstanding as of such date.
Mr. Mackay acquired the securities of the company for investment purposes. Depending on economic or market conditions or matters relating to the company, Mr. Mackay may choose to either acquire additional securities or dispose of securities of the company. A copy of Mr. Mackay's early warning report will appear on the company's profile on SEDAR and may also be obtained by contacting Mr. Mackay.
©